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Abstract: Long-term fish oil (FO) supplementation is able to improve Alzheimer’s disease (AD)
pathology. We aimed to determine the impact of short-term fish oil (FO) intake on phospholipids
composition and plaque pathology in 5xFAD mice, a widely used animal model of AD. A 3-week-long
FO supplementation administered at 3 months of age decreased the number of dense core plaques in
the 5xFAD cortex and changed phospholipids in the livers and brains of wild-type (Wt) and 5xFAD
mice. Livers of both genotypes responded by increase of n-3 and reciprocal decrease of n-6 fatty acids.
In Wt brains, FO supplementation induced elevation of n-3 fatty acids and subsequent enhancement
of n-6/n-3 ratio. However, in 5xFAD brains the improved n-6/n-3 ratio was mainly due to FO-induced
decrease in arachidonic and adrenic n-6 fatty acids. Also, brain and liver abundance of n-3 fatty acids
were strongly correlated in Wts, oppositely to 5xFADs where significant brain-liver correlation exists
only for n-6 fatty acids. Expression of omega-3 transporter Mfs2a remained unchanged after FO
supplementation. We have demonstrated that even a short-term FO intake improves the phospholipid
composition and has a significant effect on plaque burden in 5xFAD brains when applied in early
stages of AD pathology.
Keywords: Mfsd2a; docosahexaenoic acid; Alzheimer’s disease; n-3 polyunsaturated fatty acids;
amyloid-β; n-6 fatty acids
1. Introduction
The polyunsaturated fatty acids (PUFA) of omega-3 (n-3) and omega-6 (n-6) series are essential
for prenatal brain development and the normal maintenance of brain functions and vision in adults.
Since de novo synthesis of PUFA is very low within the brain, the blood must supply PUFA to the
brain either from exogenous PUFA obtained through diet or from endogenous liver synthesis from
dietary precursors [1]. In the context of the modern human lifestyle and diet, an absolute change of
omega-6/omega-3 in the food supply of Western societies has occurred over the last 150 years, raising a
ratio of omega-6/omega-3 to 20:1 instead of 1:1 as was in our ancestral diets [2]. An unbalanced
omega-6/omega-3 ratio plays an important role in the development of many chronic and inflammatory
conditions like coronary disease, diabetes, arthritis, cancer and neurological and psychiatric diseases.
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As omega-3 PUFA supplementation was shown to play a significant role in the prevention and
management of some of these conditions, in recent years omega-3 has been considered of a particular
interest for its potential to ameliorate or delay the onset of Alzheimer’s disease (AD).
Numerous studies have demonstrated that omega-3 supplementation, mainly performed through
dietary or oral administration of docosahexaenoic acid (DHA) is able to improve AD-associated
brain pathology. Thus in different transgenic mouse models of AD, omega-3 supplementation
was shown to reduce amyloid plaque burden [3–10], reduce Thau pathology [6,11],
improve learning and memory [4,5,7,9,12] decrease inflammation [4,13,14], reduce neuronal loss
and neurodegeneration [7,12,15], and improve neurogenesis and synaptic plasticity [16]. Similar effects
of omega-3 supplementation were confirmed in a rat model of AD caused by amyloid-β injections [15]
and also in a 3xTG-AD/Fat-1 mouse that can convert endogenous omega-6 to omega-3 [17].
Synthetic hydroxylated derivatives of DHA was also shown to have beneficial effects on AD
hallmarks [18–20], as well as fish oil, a natural source of omega-3 fatty acids [21,22]. These findings in
animal models are supported by epidemiological studies on humans, revealing the improvement of
mild cognitive impairment by omega-3 treatment and an inverse relation between omega-3 intake and
AD incidence, although some discordant findings still exist [1,23].
Despite the fact that PUFAs, especially DHA, are very abundant in the phospholipids of
the neural membrane, the mechanisms of their uptake into the brain are not well understood.
Extensive presence of fatty acids (FA) transporters and binding proteins indicate that they can
be critically involved in the intake and enrichment of PUFAs, although it is still unclear to what
extent simple diffusion contributes to the total rate of PUFAs intake [24]. Thus, of great importance
was the recent finding of Nguyen et al. [25] who identified Mfsd2a Mfsd2a, previously an orphan
transporter, as the major transporter for DHA uptake in the brain. Mfsd2a plays an essential role in
maintaining DHA levels during embryogenesis and in establishing the integrity of the blood–brain
barrier (BBB). Genetic ablation of Mfsd2a results in neurovascular dysfunction due to BBB leakage,
as seen in neurodegenerative disorders and AD [25,26]. Mfsd2a can be induced in mouse liver by
fasting or a high-fat diet, indicating a potential physiological role in lipid metabolism and energy
expenditure [27,28], but its expression in the presence of excessive DHA has not been evaluated.
Previous examination of post-mortem autopsy brain samples found significant DHA reduction
in AD patients that may be related to cognitive decline [1,23,29] and some clinical trials revealed a
certain recovery of cognitive capacity in patients with mild to moderate AD who were administered
omega-3 from fish oil [23]. Studies on animals demonstrated the ability of supplementation with
omega-3, DHA, DHA and EPA, or DHA derivate to change the brain fatty acid composition and to
significantly increase levels of DHA and total omega-3 PUFAs accompanied by a reciprocal decrease
of individual and total omega-6 fatty acids [3,5,7,12,21,30–32]. These changes can modify cellular
membrane structures and reduce oxidative modifications [33,34] since phospholipids with a higher
percentage of DHA have greater flexibility and less ordered packing of hydrocarbon chains that can
alter lateral movement of proteins, ion channels, and detergent-insoluble lipid rafts. Amyloidogenic
APP (amyloid precursor protein) processing, aside from intracellular compartments, is believed to
occur in lipid rafts of the synaptic membrane, the sites where APP protein and β- and γ-secretases are
located. Changes in brain DHA concentration could affect lateral mobility collision rates between APP
and secretases thus down-regulating APP processing and deposition of amyloid beta (Aβ) cleavage
product into plaques, hallmarks of AD disease [8,31,35]. Also, accumulating evidence indicates that
Aβ plays an important role in regulating lipid homeostasis, either by direct effect or influencing gene
expression/stability of enzymes involved in lipid synthesis, suggesting bidirectional link between
APP and lipids [36].
Although 5xFAD is a widely used mouse model of AD, to the best of our knowledge, there are
only few studies that have investigated the effects of omega-3 supplementation in this mouse model.
They used DHA [4] or DHA synthetic derivate HDHA [18,20,31] and showed elevated very long-chain
fatty acids (>22 carbons) and reduced Aβ production [18,20,31]. A comprehensive examination of the
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long-chain (≥16 carbons) fatty acids in the brain and liver of 5xFAD mice following short-term fish oil
(FO) treatment implemented during the early phase of AD pathology, prior to the extensive plaque
depositions, has not been undertaken previously. Therefore, in this study we aimed (1) to characterise
the lipid profile of 5xFAD mice in comparison to wild-type littermates, (2) to examine whether very
short FO supplementation affects the fatty acid composition of brain phospholipids, (3) to examine if
FO supplementation affects Mfsd2a expression, and (4) to evaluate the effects of FO on the amyloid
plaque burden in the cortex of transgenic animals. As previous evidence suggested the importance of
peripheral omega-3 fatty acids, we also performed a lipid analysis of the liver, due to its indispensable
contribution in supplying DHA and other essential fatty acids to the brain.
2. Materials and Methods
2.1. Animals
In this study we used the 5xFAD mouse model, bearing five familial AD human mutations
(3 in APP gene–Swedish, Florida, and London, and two in PS1 gene-M146L and L286V) under
transcriptional control of the neuron-specific murine Thy-1 promoter, as described by Oakley et al. [37].
5XFAD transgenic male mice were crossed with C57BL/6xSJL female mice (both obtained from Jackson
Laboratory, Bar Harbor, ME, USA). The resulting offspring (heterozygous 5xFAD transgenic and
non-transgenic, wild-type littermates as their controls) were used in experiments. Genotyping was
performed by polymerase chain reaction (PCR) of tail DNA according to the supplier’s protocol.
The animals (3–4 mice per cage) were housed under standard conditions (23 ± 2 ◦C, 60–70% relative
humidity, 12 h light/dark cycles, free access to food and water). All animal procedures were in
compliance with the Directive (2010/63/EU) on the protection of animals used for experimental
and other scientific purposes and was approved by the Ethical Committee for the Use of Laboratory
Animals (resolution No. 01-06/13) of the Institute for Biological Research, University of Belgrade.
Minimal numbers of animals were used and all efforts were made to minimize animal suffering.
2.2. Treatments
All animals were raised on commercial rodent chow (diet composition and body weights are
given in the Tables 1 and 2, respectively). At 3 months of age, animals were divided into 4 groups:
control, wild-type and transgenic groups (Wt, n = 10, and 5xFAD, n = 12, respectively) and treated,
FO-supplemented Wt and transgenic groups (Wt FO, n = 10, and 5xFAD FO, n = 12, respectively).
The 100 µL of the fish oil (fatty acid composition in Table 3) was administered to the treated groups for
21 days via oral gavage. The control groups received the same volume of the water as vehicle,
Although other oils can be used as a control for the fish oil treatment, as dietary FO contains
other fatty acids (apart from omega-3 and omega-6 fatty acids), iodine, furan fatty acids, as well
as anti-oxidant vitamin E that can have a certain biological effect per se [22] and references cited
therein), they themselves may contain some active innate or added components that may hinder
conclusions on FO direct effects. Furthermore, we avoided the comparison of the effects of two oils
(oil of interest and control oil). We applied encapsulated fish oil. In order to avoid degradation of
DHA, one capsule containing 1 mL of FO was used for each 3–4 animals (100 µL per animal) and was
administered via oral gavage in no longer than 45 s. The remaining FO was discarded and the new
capsule was used for next set of animals.
At the end of the treatment, animals were anesthetized (100 mg/kg, Ketamidor, Richter Pharma,
Wels, Austria; 16 mg/kg Xylased, Bioveta, a.s.), sacrificed, and perfused with saline solution. One brain
hemisphere was taken for fatty acid analysis (n = 6 for both control and treated groups). The cortex
of the other hemisphere was finely chopped and mixed on ice. Twenty mg of the mixed tissue was
taken for protein isolation and another 20 mg for isolation of mRNA (n = 4 for Wt and Wt FO; n = 6 for
5xFAD and 5xFAD FO). Separate brains were fixed in 4% paraformaldehyde and used for histological
staining (n = 6).
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Table 1. Pelletized commercial diet content.
Content Percentage
Protein 17.2%
Carbohydrate 60.9%
Fat 3.7%
PUFA/SFA 1.3
n-3/n-6 PUFA 0.05
fiber 5.6%
ash 7.6%
adequate amount of vitamins and minerals
SFA, saturated fatty acids; PUFA, polyunsaturated fatty acids; n-3, omega-3; n-6, omega-6.
Table 2. Body weights of 3-month-old wild-type (Wt) and 5xFAD mice before (0 week) and during
3-week-long fish oil (FO) supplementation.
Animals 0 Week 1 Week 2 Week 3 Week
Wt 20.22 ± 0.529 20.53 ± 0.629 20.88 ± 0.419 20.80 ± 0.394
Wt FO 20.98 ± 0.627 21.62 ± 0.517 21.40 ± 0.494 21.32 ± 0.346
5xFAD 21.56 ± 0.871 21.96 ± 1.352 21.85 ± 1.155 22.46 ± 1.256
5xFAD FO 21.09 ± 0.681 21.07 ± 0.802 21.03 ± 0.664 21.26 ± 0.969
Table 3. Fatty acid composition of fish oil (% w/w of total fatty acids).
FA Saturation Number of Carbons Common Name Percentage
SFA 16:0n palmitic 22.90
18:0n stearic 2.23
MUFA 16:1n-7 palmitoleic 11.90
18:1n-9 oleic 10.25
18:1n-7 vaccenic 4.54
n-6 18:2n-6 linoleic 1.67
20:3n-6 dihomo-gama-linolenic 0.29
20:4n-6 arachidonic 1.62
22:4n-6 adrenic 1.78
n-3 20:5n-3 EPA 25.51
22:5n-3 DPA 1.82
22:6n-3 DHA 15.49
SFA, saturated fatty acids; MUFA, mono-unsaturated fatty acids; n-6, omega-6 polyunsaturated fatty acids
(PUFA); n-3, omega-3 polyunsaturated fatty acids; EPA, eicosapentaenoic acid; DPA, docosapentaenoic acid;
DHA, docosahexaenoic acid.
2.3. Lipids Extraction
For the extraction of total lipids, half of the brain was homogenized in 3 mL of
chloroform/methanol (1:2 v/v). After centrifugation, the supernatants were collected and evaporated
to dryness. The residues were dissolved in 3 mL of chloroform/methanol (2:1 v/v) and 3 mL
of chloroform/methanol/KCl (4:2:1 v/v), and centrifuged to eliminate low molecular weight
contaminants. After centrifugation, the upper layer was discarded and the lower lipid layers were
used for further analysis. During the extraction procedure BHT (2,6-di-tert-butyl-4-methylphenol) was
added to the solvents (10 mg/100 mL) to protect lipids from oxidation.
Phospholipid (PL) fraction was isolated by one-dimensional thin-layer chromatography (TLC) on
Silica Gel GF plates (Merck, Darmstadt, Germany) using neutral lipid solvent system of hexane/diethyl
ether/acetic acid (87:12:1 v/v), and methyl esters of PL fatty acids were prepared by transmethylation.
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2.4. Phospholipid Analysis
Fatty acids methyl esters were separated by gas-liquid chromatography on a Shimadzu
chromatograph GC 2014 (Shimadzu Co., Tokyo, Japan), equipped with a flame ionization detector and
GC column Trace TR-Fame (100 m × 0.25 mm ID, film thickness 0.2 µm) (Thermo Fisher Scientific,
Waltham, MA, USA). The injection port was set at 220 ◦C and the flame ionization detector at 260 ◦C.
The oven temperature was programmed at 180 ◦C for 15 min and then from 180 ◦C to 240 ◦C at the
heating rate of 1.8 ◦C/min. The total separation period was 78 min. Individual fatty acid methyl esters
were identified by comparing sample peak retention times with PUFA standard mixture (PUFA-2 mix,
Supelco, Munich, Germany). Phospholipids FA profiles were expressed as the relative percentage
areas of total FA.
2.5. Western Blotting
For Western blot analysis, cortical tissue was homogenized in 10 vol (w/v) of RIPA buffer
(50 mM Tris-Cl, pH 7.5, 150 mM NaCl, 1% NP-40, 0.1% SDS, 10 mM EDTA, pH 8.0, 10 mM EGTA,
pH 7.2, 0.5% Triton X-100) that contained protease-phosphatase inhibitors (Roche, Basel, Switzerland).
Protein concentrations were determined using a Micro BCA Protein Assay Kit (Pierce Biotechnology,
Waltham, MA, USA). For extraction of Aβ for western blotting we used RIPA buffer that is stronger
than Tris-based buffer and was able to disrupt cellular and vesicular membranes and release their
content. Thus, RIPA was able to extract soluble extracellular and cytosolic Aβ forms but also vesicular
Aβ species accumulated in the LC-II positive fractions (probably autophagic vesicles), where Aβ
monomers are predominantly concentrated [38]. Proteins were loaded in equal amounts of 20 µg
per lane, electrophoresed on 12% polyacrylamide gels and transferred onto Immobilon-P membrane
(Merck Millipore, Burlington, MA, USA). After blocking (1 h in 5% non-fat dry milk dissolved in
Tris-buffered saline/0.1% Tween 20 (TBST)), membranes were incubated overnight at +4 ◦C, with rat
anti-MFSD2a antibody (catalog #10539, Abcam, 1:8000), rabbit polyclonal anti-APP (raised against
a 22 amino acid synthetic peptide derived from the carboxy-terminus of β-APP, catalog #51-2700,
Zymed) and rabbit monoclonal anti-amyloid beta 42 (raised against a peptide corresponding to amino
acids 707-713 of P05067, catalog #700254, Invitrogen, 1:500) in TBST. After washing in TBST, blots were
incubated with the horseradish peroxidase (HRP)-conjugated secondary anti-rabbit or anti-mouse
antibody (Santa Cruz, Santa Cruz, CA, USA) in TBST for 1 h at room temperature. For loading control,
each membrane was re-probed with mouse anti-actin antibody (catalog #A5315, Sigma, St. Louis, MO,
USA). The signal was detected using enhanced chemiluminescence (ECL, Amersham GE Healthcare,
Little Chalfont, UK) and subsequent exposure on X-ray film. Final analysis was performed using
image analysis program ImageQuant 5.0. (GE Healthcare, Little Chalfont, UK).
2.6. Real Time Quantitative Polymerase Chain Reaction (RT-PCR)
Total RNA from cortical tissues was isolated using Trizol reagent according to the manufacturer’s
instructions (Invitrogen, Carlsbad, CA, USA). Two micrograms of RNA were treated with 2 U of
RNase-free DNase I (Thermo Fisher Scientifics, Waltham, MA, USA) and reverse transcribed with
a High-Capacity cDNA Archive Kit (Applied Biosystems, Foster City, CA, USA). Polymerase chain
reaction (PCR) reactions (15 ng of cDNA, 0.25 µM primers, Power SYBR Green PCR Master Mix
from Applied Biosystems) were performed using the ABI 7500 in the default thermal cycling
mode. The primer sequences were as follows: mfsd2a, F5′-AGAAGCAGCAACTGTCCATTT-3′,
R5′-CTCGGCCCACAAAAAGGATAAT-3′, and b-actin, F5′-TGGACATCCGCAAAGACCTGTAC-3′,
R5′-TCAGGAGGAGCAATGATCTTGA-3′. All real time quantitative polymerase chain reaction
(RT-PCR) reactions were performed in triplicate, and in at least two independent RT reactions.
To confirm the specificity of qPCR reactions, dissociation curves were analyzed at the end of qPCR
assay. Relative mRNA levels were calculated using the comparative Ct method, and expressed as
relative values.
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2.7. Plaque Quantification
Following fixation in paraformaldehyde PFA, hemibrains were cryopreserved in graded sucrose
solutions (10–30% w/v sucrose/phosphate buffered saline PBS), frozen in isopentane cooled on dry ice
and stored at −80 ◦C. Three sections (30 µm thick, 120 µm apart) per brain were incubated in 0.01%
Thioflavin S (ThioS) solution in 50% ethanol for 8 min at room temperature (RT). The sections were cut
between −2 to −2.500 mm from the bregma according to the Allan Mouse Brain Atlas (Allen Institute
for Brain Science (2008) available at: http:/alleninstitute.org/) and collected in PBS. Stained sections
were washed briefly in 80% and 96% ethanol, rinsed in distilled water and mounted onto glass slides
using fluorescent mounting medium (Dako, Santa Clara, CA, USA). Images were captured on an Axio
Observer Microscope Z1 using an AxioVision 4.6 software system (Carl Zeiss, Oberkochen, Germany)
and digital images were exported to ImageJ (National Institute for Health) for quantitative analysis of
each section. To obtain binary image necessary for automatic particle analysis, the maximum entropy
thresholding method was chosen. Identified objects after thresholding were individually inspected to
confirm the object as a plaque or not in a blinded manner. The average of the individual measurements
in the posterior parietal association area (rectangle dimension 1000 × 735 µm) from each mouse was
calculated to compare plaque load between the control and FO-supplemented 5xFAD mice.
2.8. Statistics
Data were analyzed using Prism program (GraphPad Prism, Software, v.6, La Jolla, CA, USA).
The normality of the distributions of values obtained for each group/experimental treatment was
determined using the D’Agostino-Pearson normality test. For multiple comparisons two-way analysis
of variance (ANOVA) (FO-diet and genotype as factors) with Tukey post hoc test was used when
distribution was normal. The Kruskal–Wallis with Dunn’s test was applied when distributions were
not Gaussian. The test was considered significant when p < 0.05.
3. Results
3.1. Fish Oil (FO) Differentially Affected n-3 and n-6 Polyunsaturated Fatty Acids (PUFA) Content in the
Brains of the Wild-Type (WT) and 5xFAD Mice
As one of the aims of this study was to investigate whether a 3-week-long FO supplementation
could change compositions of phospholipids in the brains of Wt and 5xFAD animals, the first step
was to determine if there were any differences in the basal level of fatty acids between two genotypes.
Lipidomic analysis showed that levels of n-3 fatty acids (EPA, docosapentanoic acid DPA and DHA)
did not differ between Wt and 5xFAD brains (Figure 1). However, there were significant differences in
the levels of n-6 fatty acids, as omega-6 arachidonic acid (AA) and adrenic acid levels were higher by
10% (p < 0.05) and 55% (p < 0.05), respectively, in the brains of 5xFAD compared to Wt brains.
Next, we analyzed the effects of FO dietary supplementation and found significant impact on
phospholipids of both groups. The main effect of FO in the Wt group was the elevation of all n-3 fatty
acids, EPA (2-fold increase, p < 0.05), DPA (92%, p < 0.01) and DHA (17%, p < 0.05), as well as of DHGLA
(41%, p < 0.01), an n-6 fatty acid that has an anti-inflammatory role. In contrast, a dominant effect
observed in the 5xFAD group was decrease of the n-6 fatty acids, as seen in the reduced concentration
of the AA and adrenic acid levels by 21% (p < 0.001) and 35% (p < 0.01), respectively. Fish oil treatment
did not change n-3 EPA and DHA levels, but did elevate DPA by 43% (p < 0.05).
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AA, arachidonic acid (pdiet = 0.0009, pgenotype = 0.1496, pinteraction < 0.0001); (D) adrenic acid 
(Kruskal-Wallis, p = 0.0015); (E) EPA, eicosapentanoic acid (pdiet = 0.0032, pgenotype = 0.7417, pinteraction = 
0.1962); (F) DPA, docosapentaenoic acid (pdiet < 0.0001, pgenotype = 0.0831, pinteraction = 0.0224); (G) DHA, 
docosahexaenoic acid (pdiet = 0.1817, pgenotype = 0.0483, pinteraction = 0.0089); (H) omega-6/omega-3 ratio 
(pdiet < 0.0001, pgenotype = 0.0569, pinteraction = 0.0010). Data are shown as a single points per animal (circles, 
squares or triangles) in each group. Values are presented as mean ± standard deviation (SD). * p < 
0.05, ** p < 0.01, *** p < 0.001; n.s., not significant. 
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liver of Wt and 5xFAD mice. (A) LA, Linoleic acid (2-w analysis of variance (ANOVA),
pdiet = 0.0219, pgenotype = 0.3881, pinteraction = 0.7719), (B) DHGLA, dihomo-gamma-linolenic
acid (pdiet = 0.9445, pgenotype = 0.4869, pinteraction = 0.509); (C) AA, arachidonic acid
(Kruskal-Wallis, p = 0.0004); (D) adrenic acid (Kruskal-Wallis, p = 0.0009); (E) EPA, eicosapentanoic
acid ( diet < 0.0001, pgenotype = 0.5690, pinteraction = 0.0449); (F) DPA, docosapent noic ac d
(pdiet < 0.0001, pgenotype = 0.3877, pinteraction = 0.8339); (G) DHA, docosahexaenoic acid (pdiet = 0. 002,
pgenotype < 0. 001, pinteraction = 0.5067); (H) omega-6/omega-3 ratio (pdiet < 0.0001, pgenotype = 0.00084,
pinteraction = 0.0410). Data re shown as a single points per animal (circles, squares or triangles) in each
group.Values are presented as mean ± SD. * p < 0.05, ** p < 0.01, *** p < 0.001; n.s., not significant.
Following FO supplementation there were robust increases of EPA (4-fold, p < 0.001), DPA (2-fold,
p < 0.01) and DHA (27%, p < 0.05) in the phospholipids of Wt livers. In 5xFAD livers FO also induced
the rise of all n-3, but the extent of changes in EPA and DHA levels was half of that found in Wts (only
double increases of EPA, p < 0.01, and 14% of DHA, p < 0.01).
These increases in n-3 fatty acid levels ere paralleled by a significant, si ilar extent of reduction,
by ~50%, in the levels of n-6 AA and adrenic fatty acids in both Wt and 5xFAD genotypes.
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3.3. Correlation of Individual Omega-6 and Omega-3 Fatty Acids between Liver and Brain
We then sought to determine if the dietary intake of FO influences an association between liver
and brain n-3 and n-6 fatty acid levels and therefore performed a linear regression analysis (Figure 3).
Significant positive correlations were found for EPA (R2 = 0.49; p = 0.0112), DPA (R2 = 0.74, p = 0.0003)
and DHA (R2 = 0.49; p = 0.0118) between the liver and brain of Wt animals.
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Linear regression analysis of EPA, DPA, DH , AA nd adrenic acid levels (percentage of total f tty
acids) between the liver and the brain of Wt (black circles) and TG, 5xFAD mice (gray squares).
Significant correlation was found for individual n-3 fatty acids in Wt animals and for n-6 fatty acids in
5xFAD animals.
In 5xFAD animals, the increases in EPA, DPA and DHA levels in the liver were not in direct
relation with changes observed in the brain (EPA: R2 = 0.02; p = 0.66; DPA: R2 = 0.16; p = 0.19 and
DHA: R2 = 0.18; p = 0.167). However, there was a strong and significant correlation between the liver
and brain decrease of AA (R2 = 0.87; p = 0 < 0.0001) and adrenic acid (R2 = 0.78; p < 0.0001) in 5xFAD
transgenic animals.
Together, these results suggest that livers and brains of both Wt and 5xFAD genotypes were
responsive to dietary FO intake. However, a substantial correlation between liver and brain was found
only for n-3 in Wt animals, and for n-6 in 5xFAD.
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3.4. Effects of FO Supplementation on Total PUFA, Mono-Unsaturated Fatty Acids (MUFA) and Saturated
Fatty Acids (SFA) in the Brains and Livers of Wt and 5xFAD Mice
Changes in the quantity of individual fatty acids ultimately have resulted in alterations of total
n-3 and n-6 levels and the n-6/n-3 ratio in both liver and brain.
In the livers (Table 4), FO supplementation improved n-6/n-3 ratio in both genotypes as the
outcome of increased total n-3 (by 43% in Wt, p < 0.001, and 23% in 5xFAD, p < 0.001) and parallel
decrease of total n-6 levels (18% in Wt, p < 0.05 and 16% in 5xFAD, p < 0.05). Total PUFA levels did not
change noticeably.
Table 4. SFA, MUFA and PUFA in the livers of WT and 5xFAD control and FO supplemented mice.
FA (%) Wt Wt FO 5xFAD 5xFAD FO
Palmitic acid (16:0) 22.33 ± 1.48 26.56 ± 1.47 a2 20.92 ± 0.89 24.87 ± 2.10 a,b1
Stearic acid (18:0) 22.67 ± 2.61 21.57 ± 1.57 21.57 ± 1.43 21.00 ± 1.59
SFA 45.01 ± 3.09 48.13 ± 1.73 42.48 ± 1.74 45.87 ± 2.63 b
Palmitoleic acid (16:1n-7) 1.04 ± 0.30 0.83 ± 0.08 0.74 ± 0.16 0.66 ± 0.08 a
Oleic acid (18:1n-9) 8.40 ± 0.48 7.47 ± 0.59 a 7.33 ± 0.46 a1 6.56 ± 0.72 a2
Vaccenic acid (18:1n-7) 3.15 ± 0.54 2.21 ± 0.19 a1 2.58 ± 0.51 2.01 ± 0.43 a1
MUFA 12.59 ± 1.12 10.52 ± 0.67 a1 10.66 ±1.07 a 9.23 ± 1.13 a2
n-6 31.84 ± 1.81 26.21 ± 2.79 a1 33.13 ± 1.41 27.95 ± 1.12 a2,b2
n-3 10.56 ± 1.89 15.14 ± 1.35 a2 13.73 ± 0.73 a1 16.95 ± 1.48 a2,b2
PUFA 42.40 ± 3.23 41.35 ± 2.05 46.86 ± 2.00 a 44.90 ± 1.99
SFA, saturated fatty acids; MUFA, mono-unsaturated fatty acids; n-6, omega-6 polyunsaturated fatty acids (PUFA);
n-3, omega-3 polyunsaturated fatty acids. Values are presented as mean± SD. Significantly different from Wt group:
a p < 0.05, a1 p < 0.01, a2 p < 0.001. Significantly different from 5xFAD group: b p < 0.05, b1 p < 0.01, b2 p < 0.001.
The improvement of n-6/n-3 ratio was also detected in the brains of both genotypes (Table 5).
However, while in Wt animals it was a consequence of significant increase of total n-3 (19%, p < 0.05),
in 5xFAD mice it was a result of a decrease in total n-6 level (23%, p < 0.001). Accordingly, total PUFA
level in the brain after FO supplementation was elevated by 14% (p < 0.05) in Wt and reduced by 15%
(p < 0.05) in 5xFAD animals.
Table 5. SFA, MUFA and PUFA in the brains of Wt and 5xFAD control and FO supplemented mice.
FA (%) Wt Wt FO 5xFAD 5xFAD FO
Palmitic acid (16:0) 28.49 ± 1.46 25.83 ± 2.57 a 27.00 ± 1.85 29.11 ± 3.17
Stearic acid (18:0) 25.92 ± 3.0 22.94 ± 0.99 24.29 ± 2.20 26.89 ± 2.53
SFA 54.41 ± 22.69 48.77 ± 4.36 a1 51.29 ± 1.64 a 56.01 ± 4.36 b
Palmitoleic acid (16:1n-7) 0.46 ± 0.15 0.49 ± 0.13 0.37 ± 0.09 0.47 ± 0.10
Oleic acid (18:1n-9) 14.32 ± 1.52 15.02 ± 0.75 14.64 ± 1.67 14.05 ± 2.38
Vaccenic acid (18:1n-7) 3.85 ± 0.26 4.71 ± 0.54 a 4.19 ± 0.77 3.93 ± 0.61
MUFA 18.62 ± 1.87 20.40 ± 0.31 a 19.21 ± 2.33 18.45 ± 2.86
n-6 11.60 ± 0.49 12.66 ± 0.99 a 13.62 ± 0.85 a2 10.51 ± 0.66 a1,b2
n-3 15.26 ± 0.71 18.17 ± 1.84 a1 15.88 ± 1.72 15.03 ± 1.56
PUFA 26.97 ± 1.06 30.83 ± 2.75 a1 29.50 ± 2.46 a 25.54 ± 2.16 b
SFA, saturated fatty acids; MUFA, mono-unsaturated fatty acids; n-6, omega-6 polyunsaturated fatty acids (PUFA);
n-3, omega-3 polyunsaturated fatty acids. Values are presented as mean± SD. Significantly different from Wt group:
a p < 0.05, a1 p < 0.01, a2 p < 0.001. Significantly different from 5xFAD group: b p < 0.05, b2 p < 0.001.
Since analysis of FO composition showed a certain percentage of other fatty acids beside essential
PUFAs, especially palmitic, palmitoleic and oleic (Table 3), we also analysed whether FO intake
modulates brain and liver tissue content of mono-unsaturated fatty acids (MUFAs) and saturated
fatty acids (SFAs). Individual SFA had similar levels in the livers and brains of both Wt and 5xFAD
animals. Supplementation with FO, rich in palmitic acid, induced elevation of tissue palmitic acid in
Nutrients 2018, 10, 1250 11 of 19
both genotypes in the livers by 19% (p < 0.05), but total SFA change reached significance only in 5xFAD
mice. In the brain, however, palmitic acid level varied differently between genotypes, resulting in the
total SFA decrease in Wt (12%, p < 0.01) and increase in 5xFAD (9%, p < 0.05).
As for MUFA, significant though opposed effects of FO supplementation on individual and total
fatty acids were observed mainly in the liver and brain of Wt animals (Tables 4 and 5).
3.5. The Expression of Mfsd2a Transporter Remained Unchanged in the Livers and Brains of Wt and 5xFAD
Mice Following FO Supplementation
Since Mfsd2a was recognized as a specific transporter of n-3 DHA in the brain, with lower
specificity for palmitic and oleic acid [8], it was of interest to investigate whether FO intake would
influence its expression. To evaluate the specificity of Mfsd2a antibody binding, we performed several
validation steps, which included induction of a specific band by fasting [28], immunoprecipitation and
pre incubation with blocking peptide, all of which confirmed specific immunoreactivity (data not
shown). The levels of Mfsd2a mRNA and protein in the brain were not significantly different between
Wt and 5xFAD (Figure 4A,B) and no changes were observed following the FO treatment.
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Figure 4. Expression of Mfsd2a in the brain and liver of Wt and 5xFAD mice after fish oil
supplementation. The levels of Mfsd2a mRNA and protein were obtained by real-time polymerase
chain reaction (RT-PCR) (A,C) and Western blotting (B,D), respectively in the brain (left panel) and liver
(right panel) of Wt and 5xFAD animals. 03B2-actin served as an internal control of the mfsd2a gene
expression and protein load. Data are presented as mean ± SEM (standard error of mean). * p < 0.05;
n.s., not significant.
In the liver (Figure 4C,D), trong trends o enhanced translation of Mfsd2a mRNA to protein
were observed after FO supplementation, but these changes were not significant due to liver
individual differences.
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3.6. FO Supplementation Decreased the Number of Aβ Plaques in the Parietal Cortex of 5xFAD Mice
As APP processing and accumulation of Aβ forms into plaques is one of the most recognizable
hallmarks of AD pathology, we next examined whether three weeks long FO supplementation changed
amyloid burden in the cortex of 5xFAD mice (Figure 5). Western blot analysis of APP protein showed
that the 5xFAD mouse model expressed stable and significantly higher level of APP full length protein
compared to the Wt, and its expression is not altered after FO supplementation (Figure 5A). We also
analyzed the expression levels of Aβ using western blotting, and the signal intensity that we obtained
was similar to the results previously published in different transgenic models [39,40]. Our data also
showed that the FO treatment did not influence amyloid levels considering that the expression of
β-CTF and Aβ forms generated by APP proteolytic processing was unchanged. However, analysis of
tissue sections stained with Thioflavin S (Figure 5B) demonstrated that FO reduced the number of
dense-core plaques by 34% (p < 0.01) in the parietal cortex, the brain region that is one of the most
vulnerable in AD.N trients 2018, 10, x FOR PEER REVIEW  12 of 18 
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Beneficial effects of omega-3 PUFA and its major component DHA have been already demonstrated in
several animal models of AD, but the majority of studies (reviewed in [13]) have used considerably
longer omega-3 supplementation, lasting from one to more than 18 months. In contrast to some
previous studies, we compared the effects of dietary omega-3 PUFA supplementation to the effects of
a standard rodent diet that is nutritionally sufficient in lipids, which abolishes the question of whether
group differences are a consequence of increased omega-3 levels in the experimental group or low
brain omega-3 levels in the control group. Herein, we clearly demonstrated that over the short term,
a 3-week-long period of FO supplementation was able to change the phospholipids profile in the brains
and livers of both wild-type and 5xFAD transgenic AD mice. While livers of both genotypes responded
to FO with the increase of omega-3 and the reciprocal decrease of omega-6 PUFAs, changes in the
brains were more complex. We revealed that FO-dependent modulation of the lipid composition may
have beneficial effects not necessarily because of the elevation of omega-3 fatty acid levels, but rather
due to the reduction of omega-6 fatty acids.
The distinct pattern of FO-induced changes in FA composition in both Wt and 5xFAD animals is
reflective of genotype-associated differences in FA content. Namely, our data revealed significantly
higher level of omega-6 arachidonic (AA) and adrenic fatty acids in the brains of 5xFAD mice
compared to wild-type littermates, as was found, similarly, in tg2576 AD model [17], Physiologically,
AA plays important roles in synaptic signalling, long-term potentiation, learning and memory [41]
but its excessive levels could have detrimental consequences through several mechanisms. Firstly,
AA can be metabolized to eicosanoids (prostaglandins, leukotriens, and tromboxans) all of which are
potent mediators of inflammation, oxidative stress and cerebrovascular dysfunction [41,42]. Secondly,
excessive neuronal excitation induced by AA can cause excitotoxicity, and consequently synaptic
deficits, network dysfunction, and behavioural deficits [41]. Furthermore, unbound AA released by
phospholipase A2 from membrane phosphoglicerides can be elongated in a single step to adrenic
acid, the third most abundant PUFA in the brain. The specific function of adrenic acid is not yet clear,
but it could have some biological activities similar to AA as the abnormalities in AA and adrenic fatty
acid levels are implicated in the pathogenesis of Alzheimer’s disease [2]. Thus, the increased level of
arachidonic ARA and adrenic acid reported in our study can be critical for neuroinflammation and
synaptic dysfunction, AD-associated phenomena prominently present in 4-month-old 5xFAD animals.
By contrast with Wt mice and some AD models [13,21,32], where FO induced a robust
augmentation of main omega-3 fatty acids, the major effect of FO supplementation in 5xFAD brains was
the reduction of omega-6 AA and adrenic acids. This finding is of great importance as previous data
showed the correlation between brain levels of n-6 fatty acids, Aβ1–40 levels and cognitive performance
in transgenic AD mice [43]. The correlation between AA intake and production of its respective derived
pro-inflammatory eicosanoids [1], further points to AA and probably adrenic acid as interesting and
manageable targets in nutrition-based preventive strategies against AD.
Along with the reduction in omega-6 FA, in 5xFAD brains we also found the FO-induced rise of
DPA, one of the omega-3 fatty acids that is an intermediary in the EPA–DHA pathway. The increase of
DPA was also significant in the brains of Wt animals. Since DPA was mainly observed as a potential
reservoir for EPA and DHA [44], only a few studies have investigated DPA’s independent effects
so far, establishing its role as a potent inhibitor of AA metabolism [32,44]. This is substantial as the
proinflammatory eicosanoids derived from AA are biologically active in very small quantities [2]
and any reduction in their presence may be beneficial for AD pathogenesis. Accordingly, we could
presume that FO-induced elevation of DPA in 5xFAD brains is the most favorable outcome at a given
circumstance due to its potent AA diminishing effects.
In our study, surprisingly, the 3-week-long FO treatment induced only a modest increase in
DHA levels in the livers of both genotypes and in the brain of Wts, while in the brain of 5xFAD mice
the DHA level was unaltered. Dietary conditions significantly influence the content of long-chain
PUFAs–especially DHA in the CNS [24]. Unlike our study, numerous studies on other animal models
found elevation of DHA after dietary or oral supplementation with DHA in the cortical or hippocampal
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tissues, especially of females [3,5,6,8,12,15]. One of the reasons for this discrepancy could be slower
accumulations of DHA and EPA in the 5xFAD brain. Previously, it was shown that the rate and length of
time needed to complete DHA recovery after chronic depletion were specific for tissues, taking 2 weeks
in the liver, while cerebral DHA levels do not return to normal until 8 weeks later [45]. It is possible that
uptake and delivery of the nervous system are not capable of rapid DHA accumulation in the brain due
to transport-related process at the blood–brain barrier that are rate-limiting [45]. This would be in line
with unaltered Mfsd2a protein expression found in 5xFAD. Very heterogenic mRNA expression not
in accordance with protein level [46] and inconsistent induction of other fatty acid transporters (like
FABP5) by FO in transgenic models [21] are already shown, possibly indicating complex mechanisms
involved in transporters’ regulation and likely numerous posttranslational modifications. Although
we can’t rule out the role of transporters, since livers of 5xFAD did elevate DHA levels making it
available for the brain.
The additional explanation for unaltered DHA and EPA levels after dietary supplementation in
5xFAD may be their catabolism to more potent anti-inflammatory and neuroprotective metabolites
after entering the brain. The synthesis of resolvins and protectins from DHA and EPA as precursors
is increased within 3–4 weeks in blood or peripheral tissue of both human and rodents taking an
omega-3 enriched diet, as well as in in vitro studies [47–49]. However, this is questionable as the
mediators are generated at very small concentrations and the half-life of their original precursors,
EPA and DHA, in the brain is much longer [1]. We could also speculate that the disparity of our results
regarding DHA elevation may reside in the use of fish oil that normally contains higher amounts of
EPA than DHA as a source of omega-3, since the most of published data were obtained following
DHA application (reviewed in [50]). Both fatty acids may have distinct functions in the brain and an
optimal outcome may be met by FO of different EPA–DHA ratios [24,44]. Notably, FO contains other
fatty acids, apart from omega-3 and -6, along with other components (iodine, furan fatty acid, as well
as anti-oxidant vitamin E) that can have certain biological effects per se [21–23,43]. Although the
recent study by Dong et al. (2018) [21] confirmed positive effect of FO administration on DHA
level in APP/PS1 transgenic model, results of our study are to a large extent supported by data of
Arendash et al. (2007) [43], which have shown no effect of long-term FO feeding on cortical omega-3
fatty acids and soluble/insoluble Aβwithin the hippocampus, but suggested benefits of FO, at least
in low-risk individuals, through corrections of omega-6 level. Our data strongly suggest that even
short-term FO treatment can have positive effects in genetically modified animals that are mediated
via the reduction of AA and adrenic omega-6 fatty acids and elevation of DPA, not DHA.
One of the hypotheses underlying the present study was that the short-term FO supplementation
in 5xFAD mice would alter AD brain pathological markers, i.e., Aβ aggregations into the amyloid
plaques. Indeed, FO supplementation induced a significant reduction in the number of Thioflavin
S positive dense-core plaques in the parietal association cortex, the part of the parietal lobe whose
role in the development of AD has gained significant attention [4,51]. However, the unaltered level
of the full length APP protein and its cleaved Aβ product, along with an unchanged level of DHA
incorporation into phospholipids, indicated that potential structural changes in neuronal membranes
influencing Aβ generation, may not be the main mechanism of FO beneficial effects in our study.
These results are in line with some other studies showing positive effects of omega-3 in transgenic
mouse that were not necessarily accompanied by the reduction of brain Aβ [3,5,43,52]. One of the
plausible explanations could be that the beneficial effects of DHA in AD can be increased by other
specific nutrients found in FO or added to FO-enriched chow as antioxidant vitamin E, which has
recently been shown to promote the effects of FO [21]. Other mechanism, suggested by Teng et al.,
(2015) where DHA effects are not directly attributable to the inhibition of Aβ production, pointed to
downstream process of oligomerization through the increase of DHA-mediated less toxic fibrilar vs.
more toxic prefibrilar Aβ species. Similar DHA-associated modulation of Aβ aggregation could not be
excluded as a potential cause of reduced plaque numbers in our study since short-term FO may likely
affect plaque seeding and formation of new plaques than induce the reduction of already existing dense
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core plaque deposits. Additionally, there were indications that Aβ aggregation into plaques could be
hindered by omega-3 immuno-modulatory action. Namely, the 5xFAD model is characterized by a
rapid and massive accumulation of Aβ in the brain that induces a robust inflammatory response [37]
and sustained microglia activation becomes the predominant feature in 5xFAD model from 4 to
9 months of age [53]. We believe that FO-mediated improvement of the omega-6/omega-3 ratio,
induced specifically by a decrease of pro-inflammatory AA and adrenic fatty acids, might stimulate
microglia to convert to activation state associated with defence and anti-inflammatory mechanisms [54]
in this early phase of AD pathology. This is corroborated with the latest results from our laboratory
(data submitted for publication) demonstrating that following a 3-week-long FO supplementation the
increased microglia accumulation around plaques acted as a barrier preventing soluble Aβ to bind
to dense, compact plaques. Notably, the importance of the microglia barrier is the most prominent
at the initial stage of fibrillar amyloid deposition and becomes less effective as plaques grow in
size [55]. When a certain critical concentration of Aβ oligomeric form is achieved, plaques form quickly
and grow to a mature, stable size within days and that short period may be the time-frame for glial
action [56]. As 5xFAD mice before the age of 4 months are in the mild/moderate phase of AD pathology,
during the early stage of Aβ accumulation and with no intensive inflammation yet, the 3-week-long
FO supplementation could contribute to microglia-mediated activation of protective mechanisms and,
thus, attenuate the birth of new plaques and/or modulate the degree of plaque compaction.
There are few limitations of this study. It is possible that longer treatment would be useful in
deciphering if 5xFAD mice need more time than Wt littermates to accumulate DHA and EPA and
whether it would change Mfsd2a transporter expression. Also, we cannot exclude the possibility that
the changes in subcellular localization (lipid rafts) or the distribution of specific phospholipid classes
in different brain regions [30] might give valuable information, especially regarding DHA. The studies
on the effect of DHA differ in many factors, including animal species and genotype, age and extent
of AD pathology, dose, duration of supplementation, route of administration and prior deprivation
of omega-3 in the diet, all of which could affect DHA levels and make comparisons between them
difficult. These questions are subjects for the future studies. However, this work has revealed several
very important facts regarding the potential of specific nutritional factors, even if applied short term,
to alleviate the pathogenesis of AD.
5. Conclusions
Taken together, our results demonstrated that an early stage of AD pathology in 5xFAD mice
model is characterized with elevated levels of omega-6 PUFA, specifically AA and adrenic fatty acid,
whose abundance can be efficiently decreased by FO supplementation. Controlling the presence and
the ratio of omega-3 and omega-6 PUFAs in the body, especially in the liver and brain, is crucial for
optimal brain functioning [2] and can be preventative and therapeutic for a wide range of human
diseases including neurodegenerative disorders. Supplementation that usually lasts for months in
animal models would require changes in the lifestyle which may be considered as an obstacle in
omega-3 wider, preventive usage in the human population. However, we documented that nutritional
environmental factors like omega-3 supplementation, even over a duration as short as 1–3 weeks,
particularly if applied at the early stage of pathology, could have health-promoting effects despite
existing unfavorable genetic factors.
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